Abstract
Protein therapeutics, such as antibodies, enzymes and toxins, are very promising reagents for the treatment of human disease. However, many therapeutic proteins are known to elicit immune responses when administered to humans. Certain antibodies work by neutralization; others reduce drug efficacy. It is clear that helper T cells are an important factor in the development of class-switched and affinity-maturated anti-therapeutic protein antibodies. Elimination of the T cell epitope seems reasonable, but it is probably impossible to remove all T cell epitopes from protein drugs because T cell epitopes are closely related to the major histocompatibility complex (MHC) molecules, which are known to be highly polymorphic. Accordingly, a possible practical approach for reducing immunogenicity involves the removal of B cell epitopes. In this case, reducing the affinity between the antigen and the B cell receptor may reduce B cell activation, even though the T cell will still be activated. Also a B cell epitope is not restricted by MHC class II molecules. This review seeks to address the identification and the characterization of B cell epitopes, and reports on the development of strategies for reducing immune response with modified B cell epitopes.
Keywords: Toxin, antibody, B cell epitope, ELISA, conformational epitope
Current Drug Targets
Title: Reducing the Immunogenicity of Protein Therapeutics
Volume: 10 Issue: 2
Author(s): Masanori Onda
Affiliation:
Keywords: Toxin, antibody, B cell epitope, ELISA, conformational epitope
Abstract: Protein therapeutics, such as antibodies, enzymes and toxins, are very promising reagents for the treatment of human disease. However, many therapeutic proteins are known to elicit immune responses when administered to humans. Certain antibodies work by neutralization; others reduce drug efficacy. It is clear that helper T cells are an important factor in the development of class-switched and affinity-maturated anti-therapeutic protein antibodies. Elimination of the T cell epitope seems reasonable, but it is probably impossible to remove all T cell epitopes from protein drugs because T cell epitopes are closely related to the major histocompatibility complex (MHC) molecules, which are known to be highly polymorphic. Accordingly, a possible practical approach for reducing immunogenicity involves the removal of B cell epitopes. In this case, reducing the affinity between the antigen and the B cell receptor may reduce B cell activation, even though the T cell will still be activated. Also a B cell epitope is not restricted by MHC class II molecules. This review seeks to address the identification and the characterization of B cell epitopes, and reports on the development of strategies for reducing immune response with modified B cell epitopes.
Export Options
About this article
Cite this article as:
Onda Masanori, Reducing the Immunogenicity of Protein Therapeutics, Current Drug Targets 2009; 10 (2) . https://dx.doi.org/10.2174/138945009787354511
DOI https://dx.doi.org/10.2174/138945009787354511 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Perspectives in Biomolecular Therapeutic Intervention in Cancer: From the Early to the New Strategies With Type I Interferons
Current Medicinal Chemistry Significant Changes in D2-like Dopamine Gene Receptors Expression Associated with Non- Small -Cell Lung Cancer: Could it be of Potential Use in the Design of Future Therapeutic Strategies?
Current Cancer Therapy Reviews Combining Bevacizumab with Radiation or Chemoradiation for Solid Tumors: A Review of the Scientific Rationale, and Clinical Trials
Current Angiogenesis (Discontinued) Regulation of Adrenomedullin and its Family Peptide by RAMP System – Lessons from Genetically Engineered Mice
Current Protein & Peptide Science RAGE: A Multi-Ligand Receptor Unveiling Novel Insights in Health and Disease
Current Medicinal Chemistry Genetic Polymorphisms of Drug Metabolizing Enzymes and Transporters: The Long Way from Bench to Bedside
Current Topics in Medicinal Chemistry New Approach to Cancer Therapy: The Application of Signal Transduction to Anti-Cancer Drug
Current Medicinal Chemistry - Anti-Cancer Agents Microalgal Fatty Acids and Their Implication in Health and Disease
Mini-Reviews in Medicinal Chemistry Recent Advances in the Probe Development of Technetium-99m Molecular Imaging Agents
Current Organic Synthesis Obesity and Inflammation: Colorectal Cancer Engines
Current Molecular Pharmacology Non-Invasive Cell Tracking in Cancer and Cancer Therapy
Current Topics in Medicinal Chemistry Pharmacology and Chemistry of Diabetes mellitus and Antidiabetic Drugs: A Critical Review
Current Medicinal Chemistry Polymer Nanoparticles - A Novel Strategy for Administration of Paclitaxel in Cancer Chemotherapy
Current Medicinal Chemistry Biological Rationales and Clinical Applications of Temperature Controlled Hyperthermia - Implications for Multimodal Cancer Treatments
Current Medicinal Chemistry The Role of cMet in Non-Small Cell Lung Cancer Resistant to EGFRInhibitors: Did We Really Find the Target?
Current Drug Targets Resveratrol-Mediated Reversal of Tumor Multi-Drug Resistance
Current Drug Metabolism First Ayurvedic Approach Towards Green Drugs: Anti Cervical Cancer-Cell Properties of Clerodendrum viscosum Root Extract
Anti-Cancer Agents in Medicinal Chemistry A Short Overview on the Biomedical Applications of Silica, Alumina and Calcium Phosphate-based Nanostructured Materials
Current Medicinal Chemistry Functional Imaging Combined with Multi-Detector CT: A Radionuclide Imaging Perspective
Current Medical Imaging Recent Developments on 1,2,4-Triazole Nucleus in Anticancer Compounds: A Review
Anti-Cancer Agents in Medicinal Chemistry